Clinical Trial: Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma

U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07369895) titled 'Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma' on Jan. 19.

Brief Summary: This study is a single-center, open and dose-escalation clinical study to evaluate the safety, tolerability, PK/PD characteristics and preliminary efficacy of the investigational drug O&D-001 injection in the treatment of relapsed or refractory multiple myeloma.

Study Start Date: Oct. 28, 2025

Study Type: INTERVENTIONAL

Condition: Relapsed or Refractory Multiple Myeloma

Intervention: BIOLOGICAL: Chimeric antigen receptor T cell O&D-001 injection targeting BCMA and GPRC5D

Using the traditional 3+3 dose es...